St. Kevin's Church, Camden Row, Dublin

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

Retrieved on: 
Monday, July 17, 2023
ACT, Athira Pharma, Cognition, Associate Director of National Intelligence and Chief Information Officer, Neuron, Drug development, GFAP, Glial fibrillary acidic protein, Doctor of Philosophy, Phosphorylation, Macrophage, AFL, Deficit spending, Mini–Mental State Examination, Toxicity, LPS, Biomarker, Inflammation, Pathology, Bangladesh Technical Education Board, Plasma, St. Kevin's Church, Camden Row, Dublin, AAIC, Oxidative stress, Patient, Amyloid, Poster, Pharmacology, ALS, FTD, Conference, Alzheimer's disease, Neuroinflammation, Pharmaceutical industry, Medical imaging, Vaccine, Aroma compound, MMSE

BOTHELL, Wash., July 17, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system. The data are being presented in three poster presentations at the Alzheimer’s Association International Conference (AAIC) 2023, taking place July 16 – 20, 2023, virtually and in Amsterdam, Netherlands.

Key Points: 
  • “These findings underscore the potential clinical utility of biomarkers of neurodegeneration and neuroinflammation in Alzheimer's disease, and help elucidate the neuroprotective mechanisms of this promising product candidate,” said Hans J. Moebius, M.D., Ph.D., Chief Medical Officer of Athira Pharma.
  • This was a post-hoc analysis of the randomized, placebo-controlled Phase 2 ACT-AD study and data from the open-label extension study in patients with mild-to-moderate Alzheimer’s disease.
  • NfL and GFAP improvements significantly correlate with a composite score of cognition and function, further supporting the clinical utility of these biomarkers.
  • The information presented in this press release is solely the responsibility of Athira Pharma and does not necessarily represent the official views of the National Institutes of Health.

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Retrieved on: 
Tuesday, April 25, 2023
ACT, Molecule, Athira Pharma, Cognition, HGF, Enzyme inhibitor, GFAP, AFL, AAN, CFB, Survival, Deficit spending, American Academy, Donepezil, Biomarker, Inflammation, Bangladesh Technical Education Board, Model, Plasma, St. Kevin's Church, Camden Row, Dublin, Oxidative stress, Hepatocyte growth factor, Patient, AKT, Neuroprotection, Amyotrophy, Annual general meeting, American Academy of Neurology, ALS, IND, MMSE, Dopaminergic, Neurotoxicity, Excitotoxicity, Neuroinflammation, Pharmaceutical industry, Management, Medical imaging, Medical device, Aroma compound, Neurotrophic factors

BOTHELL, Wash., April 25, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of new data from its small molecule programs enhancing the HGF/MET neurotrophic system. The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass. and virtually.

Key Points: 
  • The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass.
  • “These and other data presented at this year’s AAN Annual Meeting further support other previously reported post hoc findings from ACT-AD that showed improvements in plasma biomarkers and measures of cognition.
  • Additionally, we reported new data that further elucidate the interaction between fosgonimeton and AChEIs.
  • The information presented in this press release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Retrieved on: 
Thursday, March 23, 2023
ACT, Insurance, HGF, Enzyme inhibitor, Society, Doctor of Philosophy, Athira Pharma, G&A, Open-label trial, St. Kevin's Church, Camden Row, Dublin, Neurotherapeutics, Dementia, Journal, District court, Investment, Administration, Neuropathic pain, Annual general meeting, MET, Lewy body, Growth, Research and development, R, ALS, IND, Douglas v. U.S. District Court ex rel Talk America, Conference, Publishing, Hepatocyte growth factor, Fine chemical, Pharmaceutical industry, Management, Cryptocurrency

BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.
  • We are targeting to complete enrollment of the LIFT-AD trial in mid-2023 and to have topline data in early 2024.
  • Fosgonimeton (ATH-1017) - Small molecule designed to enhance the activity of the HGF/MET system with the potential to protect and repair neuronal networks.
  • As of year-end 2022, greater than 85% of participants who have completed either study have elected to enroll in the OLEX trial.

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Retrieved on: 
Tuesday, January 31, 2023
Neurodegeneration, Washington State University, St. Kevin's Church, Camden Row, Dublin, Athira Pharma, University of Idaho, Doctor of Philosophy, University, Management, Research, L. Athira Krishna, Microbiology

BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.

Key Points: 
  • BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.
  • “Kevin is a driving force behind our research at Athira.
  • He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET pathway and its potential applications for the treatment of neurodegenerative disorders,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • in Microbiology from the University of Idaho and his Ph.D. in Molecular Biosciences from Washington State University.

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

Retrieved on: 
Wednesday, November 10, 2021
ACT, Securities Exchange Act of 1934, Cognition, Safety, Completeness, Private Securities Litigation Reform Act, G&A, Dementia, Phase II, ERP, Behavior, MET, SHAPE, R, Security (finance), NASDAQ, Neurology, Research and development, Food, Investment, LIFT, UC, COVID-19, Instagram, Administration, Research, Securities Act of 1933, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, St. Kevin's Church, Camden Row, Dublin, Twitter, Doctor of Philosophy, UC Davis Health Stadium, U.S. Securities and Exchange Commission, Lists of diseases, GLOBE, Conference, LinkedIn, Athira Pharma, Nature, EVP, Neurodegeneration, Hepatocyte growth factor, Central nervous system, Patient, Lewy body, FDA, IND, Fine chemical, Pharmaceutical industry

BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported its financial results for the third quarter ended September 30, 2021, and provided an update on the company’s operations.

Key Points: 
  • Athira is targeting an IND submission to the U.S. Food and Drug Administration (FDA) by the end of 2021.
  • R&D expenses were $10.7 million for the quarter ended September 30, 2021, as compared to $5.8 million for the same quarter in 2020.
  • G&A expenses were $7.1 million for the quarter ended September 30, 2021, as compared to $1.6 million for the same quarter in 2020.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

Retrieved on: 
Friday, October 29, 2021
ACT, St. Kevin's Church, Camden Row, Dublin, Neurology, ERP, MET, LinkedIn, IR, Athira Pharma, Twitter, HGF, Patient, Calendar, NASDAQ, Lists of diseases, PT, Review, Dementia, Brain, Discovery, Hepatocyte growth factor, Instagram, Cognition, Clinical trial, UC, Trial of the century, Neurodegeneration, L. Athira Krishna, GLOBE, UC Davis Health Stadium, Pharmaceutical industry

The webinar will be webcast live on Friday, Nov. 5, at 9 a.m. PT / 12 p.m.

Key Points: 
  • The webinar will be webcast live on Friday, Nov. 5, at 9 a.m. PT / 12 p.m.
  • , a board-certified behavioral neurologist who specializes in the treatment of cognitive disorders and age-associated neurodegenerative diseases.
  • Dr. Moebius will review Athiras clinical development program and discuss the utility of ERP P300 latency in Athiras completed Phase 1 and ongoing Phase 2 ACT-AD trial of ATH-1017.
  • Athira is measuring ERP P300 latency in a clinical trial of its investigational drug, ATH-1017, for the treatment of mild-to-moderate Alzheimers disease to evaluate a connection between this functional measurement and improved cognition.